- As of November 2026, we could not identify any completed, published clinical trial that systematically collected adverse events for KPV in human participants. Its side effect profile is uncharacterized, not established as benign.
- The absence of published side effect reports is not evidence of safety. Research peptides sit outside the pharmacovigilance systems that detect adverse reactions to approved medicines.
- Published KPV research is preclinical: cell culture and rodent models of colitis. Those studies were designed to measure anti-inflammatory activity, not toxicity, and no formal toxicology program for KPV appears in the peer-reviewed literature.
- KPV is the C-terminal fragment of alpha-MSH. That relationship supports a biological rationale, but it does not let KPV inherit the safety record of alpha-MSH, and it does not rule out effects seen with other melanocortin compounds.
- Oral, topical and injectable use raise different unknowns. Injectable use adds sterility, endotoxin and impurity exposure that the other routes do not.
- KPV holds no marketing authorization from the FDA or the EMA. Appearing on, or being removed from, a compounding list is an administrative event, not a safety determination.
- Published analyses of peptides bought from illegal online sellers have found large deviations between labeled and actual content, plus arsenic and lead contamination. Some reactions attributed to a peptide may come from what else is in the vial.
What is actually known about KPV side effects?
The honest answer is uncomfortable: the side effect profile of KPV is not characterized. KPV, the tripeptide Lys-Pro-Val, has not been through the process that produces a side effect list. There is no published adverse event table for it, no incidence figures, no distinction between common and rare reactions, and no description of what an overexposure looks like in a person.
This matters because of how side effect information is normally generated. For an approved medicine, the list on the package insert comes from controlled trials in which investigators actively asked participants about symptoms, ran laboratory monitoring, and compared the treated group against a placebo group. After approval, national pharmacovigilance systems collect spontaneous reports from clinicians and patients for years. Neither step has happened for KPV. Research peptides are purchased privately, used without medical supervision in most cases, and almost never reported to any regulator, so there is no mechanism that would surface a signal even if one existed.
What circulates instead is anecdote: forum posts, vendor pages, and clinic marketing describing KPV as well tolerated, with occasional mentions of injection site redness, mild nausea, headache or fatigue. These accounts share the same weaknesses. They have no denominator, so a handful of reports cannot be converted into a rate. They have no comparator, so a symptom cannot be separated from coincidence. And they almost never identify what was actually in the product used, which is a serious problem for an unregulated supply chain.
An absence of reported harm is not a finding of safety. It is a measurement that was never taken. A compound can be genuinely well tolerated, or it can simply be used by too few people, for too short a time, under too little observation, for a problem to become visible. Nothing in the published record currently distinguishes those two possibilities for KPV.
This article is for educational purposes only and does not constitute medical advice. It describes what the scientific literature does and does not establish. Any decision about a substance that is not approved for human use belongs with a qualified healthcare professional who knows your medical history.
Has KPV been tested in a published human clinical trial?
As of November 2026, a search of the published literature and of clinical trial registries does not identify a completed, published interventional trial of KPV in human participants, in any indication or by any route. The peer-reviewed body of work on this tripeptide is preclinical: experiments in cultured cells and in rodent models, almost entirely focused on intestinal and skin inflammation.
Reviews of the melanocortin system reflect that position. The 2023 review in Cells by Gravina and colleagues on melanocortins in inflammatory bowel disease discusses KPV and its derivative KdPT in terms of mechanism and therapeutic potential, which is the language researchers use for compounds that have not yet been tested in patients. Nothing in that literature describes a human safety dataset.
It is worth being explicit about what a first-in-human study would have produced, because each item on that list is currently missing for KPV. A phase 1 trial reports how the compound behaves in the human body, including absorption, distribution, elimination and half-life. It reports whether the immune system generates antibodies against the compound or its impurities. It reports laboratory changes in liver, kidney and blood count parameters under observation. It reports the symptoms participants experienced, how often, and how they compared with placebo. And it establishes an exposure range that was tolerated under medical supervision.
None of that information exists for KPV in humans. Statements that KPV has shown no serious toxicity in people are therefore not supported: there is no human dataset in which serious toxicity could have been observed or excluded. The correct description is that human safety is unstudied.
Two further gaps deserve mention. First, there is no published human pharmacokinetic data, so it is not known how long KPV persists in circulation, whether it reaches the tissues people hope to affect, or how it is cleared. Second, there is no published work on interactions with medicines, which is especially relevant because people interested in KPV often have inflammatory conditions and are already taking immunomodulating drugs. You can find the broader background on the molecule itself in our KPV peptide guide.
What did animal and cell studies report about tolerability?
The preclinical record is real, and it is worth describing accurately rather than dismissing. In Gastroenterology in 2008, Dalmasso and colleagues showed that KPV is taken up by the di/tripeptide transporter PepT1 in intestinal epithelial and immune cells, and that KPV given orally reduced the severity of two chemically induced colitis models in mice, DSS and TNBS, with lower expression of pro-inflammatory cytokines.
The same year, Kannengiesser and colleagues reported in Inflammatory Bowel Diseases that KPV improved outcomes in murine colitis models, with earlier recovery and better weight regain in DSS colitis, and survival of melanocortin 1 receptor deficient mice that would otherwise have died. That last result is mechanistically important: it indicates the effect is at least partly independent of MC1R signaling. In 2010, Laroui and colleagues reported in Gastroenterology that KPV delivered in nanoparticles embedded in an alginate and chitosan hydrogel, targeted to the colon, reduced inflammatory and histological damage in DSS colitis in mice.
Here is the critical reading point. These were efficacy studies, not toxicology studies. Their endpoints were disease activity, histology and cytokine expression. They were not designed to detect harm, and they did not carry the elements a regulator requires before human exposure: repeat administration toxicology in two species under good laboratory practice, genotoxicity testing, reproductive and developmental toxicity, safety pharmacology on cardiovascular and central nervous system endpoints, and immunotoxicity assessment. No such program for KPV appears in the peer-reviewed literature.
The animals themselves also limit what can be inferred. Rodent studies typically use young, genetically uniform, healthy animals, housed in controlled conditions, observed for days to a few weeks. They are not older adults with cardiovascular disease, not people on five concurrent medications, not pregnant women, and not children. Species differences in peptide transporters, protease activity and immune regulation are substantial, and short observation windows cannot detect slow processes.
Reading "no overt toxicity was observed" in a rodent efficacy paper therefore means something narrow: within that experiment, at those exposures, over that duration, the investigators did not record obvious harm in the parameters they happened to measure. It is a reasonable basis for continuing research. It is not a basis for predicting what happens in a person over months.
Why does the link to alpha-MSH prove less than it appears to?
KPV is the C-terminal tripeptide of alpha-melanocyte-stimulating hormone, corresponding to residues 11 to 13 of that thirteen amino acid hormone. In their 2008 review in Endocrine Reviews, Brzoska and colleagues explain why researchers became interested in the fragment: the pigmentary effect of alpha-MSH limits its use as an anti-inflammatory agent, while KPV appears to retain anti-inflammatory activity without that pigmentary action. Luger and Brzoska made a similar argument in Annals of the Rheumatic Diseases, describing alpha-MSH related peptides as a candidate class of anti-inflammatory and immunomodulating agents.
What this heritage legitimately supports is a mechanistic rationale. Alpha-MSH is an endogenous regulator of inflammation, melanocortin receptors are present on immune and epithelial cells, and cell work on KPV has described interference with pro-inflammatory signaling including the NF-κB pathway. That is a coherent biological story, and it explains why the molecule attracted research attention.
What the heritage does not support is a transfer of safety. Three points make that clear. First, a fragment is a different molecule with different receptor interactions, different stability and different distribution, so it does not inherit the record of the parent hormone. Second, the fact that endogenous alpha-MSH circulates in the body says nothing about the consequences of introducing a synthetic fragment from outside, at quantities and in patterns the body does not generate itself. Physiological regulation depends on where, when and how much a signal appears, not merely on whether the body recognizes the molecule.
Third, the melanocortin family cuts in the other direction too. Synthetic melanocortin receptor agonists used in humans are associated with recognized effects including nausea, flushing, blood pressure changes and pigmentary changes. Those cannot simply be assigned to KPV, which was selected precisely for lacking the pigmentary action, but they cannot be excluded either, because the receptor and non-receptor targets of KPV are not fully defined. The Kannengiesser finding that KPV worked in MC1R-deficient mice means that at least part of its activity runs through a pathway that has not been completely mapped. An incompletely mapped mechanism is an incompletely mapped side effect profile.
One additional wrinkle deserves mention. Cutuli and colleagues reported in the Journal of Leukocyte Biology in 2000 that alpha-MSH peptides inhibited Staphylococcus aureus colony formation and reduced viability and germ tube formation of Candida albicans, with the C-terminal KPV sequence present in the most active fragments. Those findings have not been consistently reproduced in later work, and they illustrate how much about this tripeptide remains contested rather than settled.
Do oral, topical and injectable use share the same unknowns?
No. The three routes people discuss raise different questions, and conflating them produces misleading reassurance. This section describes the differences; it does not recommend any route, and none of them has established human safety data.
The oral route is the one with the most direct preclinical support, because Dalmasso and colleagues showed uptake through PepT1 and an effect of orally administered KPV in mouse colitis. Two cautions follow. PepT1 expression differs between species and between individuals, and in humans it is normally concentrated in the small intestine while being induced in the colon during inflammatory bowel disease, meaning the transport picture is not identical in a healthy person and a patient. And PepT1 also transports several classes of medicines, which raises an unstudied possibility of competition. The practical unknowns of oral products are discussed further in our article on oral KPV.
The topical route faces a physical obstacle. KPV is small but hydrophilic and charged at physiological pH, and the stratum corneum is an efficient barrier to exactly that kind of molecule. Without a delivery system, meaningful penetration into deeper skin layers is not something that can be assumed. The risks of a topical preparation are therefore mostly local and mostly not about KPV itself: irritation, contact sensitization, and reactions to preservatives, solvents and other excipients whose composition is usually undisclosed.
The injectable route bypasses every biological barrier the body uses to filter what enters it. That changes the risk picture independently of the molecule. Material prepared and sold as a research chemical is not manufactured to the sterility and endotoxin standards required of an injectable medicine, and anything present as an impurity enters the circulation directly. Injection site reactions, infection and systemic reactions to contaminants are foreseeable consequences of the route, and they would be foreseeable for any substance handled the same way.
| Route | Preclinical evidence that exists | Principal unknowns |
|---|---|---|
| Oral | PepT1-mediated uptake and reduced colitis severity in mouse models | Human absorption, degradation in the digestive tract, competition with PepT1 substrate medicines, effects on the gut microbiota |
| Topical | Animal and cell work on skin inflammation; delivery system research | Penetration through human skin, local irritation and sensitization, undisclosed excipients |
| Injectable | Rodent studies in inflammation models | Sterility and endotoxin exposure, injection site reactions, direct systemic exposure to impurities, no human data of any kind |
The common denominator across all three is that human tolerability has not been measured for any of them. For a wider view of how this compares with other compounds discussed in the same context, see our overview of peptides studied for inflammation.
What risks follow in theory from dampening inflammatory signaling?
The risks in this section are theoretical, derived from pharmacological reasoning rather than from observations in people using KPV. They are listed because responsible risk assessment covers plausible mechanisms, not only documented events. None of them has been demonstrated with this tripeptide in humans.
Host defense. Inflammation is a defensive process. Pharmacological classes that suppress inflammatory signaling, from corticosteroids to biologic agents targeting cytokines, carry a recognized increase in infection risk, and that association is a class property of effective immunosuppression rather than a quirk of any one drug. If KPV meaningfully inhibits pro-inflammatory signaling in humans, the same question applies to it. If it does not inhibit that signaling meaningfully in humans, then the benefits attributed to it do not apply either. The two questions are linked and neither has been answered.
Tissue repair and surveillance. Inflammatory signaling also participates in wound healing and in immune surveillance. Sustained modulation of those processes has consequences that short rodent experiments are not designed to detect, and that would require long follow-up in humans to characterize.
Interactions with medicines. PepT1, the transporter implicated in intestinal KPV uptake, also carries several drug classes, including certain beta-lactam antibiotics, some ACE inhibitors and some antiviral prodrugs. Competition at a shared transporter is a standard pharmacokinetic interaction mechanism. Whether it occurs with KPV at any relevant level of exposure has not been studied, which means the interaction cannot be predicted or ruled out.
Immune reactions to the product. Very short peptides are generally less likely than large proteins to provoke an antibody response on their own. The relevant concern for unregulated material is different: aggregates, residual synthesis reagents, truncated sequences and bacterial endotoxin can all drive reactions, and an injectable preparation delivers them directly. A reaction experienced after using such a product cannot be attributed to the tripeptide without knowing what else the vial contained.
Populations with no data at all. Pregnancy, breastfeeding, childhood and adolescence, significant liver or kidney impairment, active malignancy and established immunodeficiency are all situations in which there is no evidence whatsoever regarding KPV. In regulatory terms these are not low-risk groups by default; they are groups in which exposure to an uncharacterized compound carries the least justifiable uncertainty.
Is KPV approved as a medicine anywhere?
No. KPV holds no marketing authorization as a medicinal product from the US Food and Drug Administration or the European Medicines Agency, and we could not identify an approval from any comparable regulator. It has not been evaluated and cleared for the prevention or treatment of any condition in humans.
Approval is not an administrative formality. It is the point at which an independent agency examines the full manufacturing record, the toxicology package, the clinical trial data and the proposed labeling, and concludes that the benefits outweigh the risks for a defined population under defined conditions of use. That examination is also what produces an authoritative side effect list. For KPV, the examination has not taken place, so the list does not exist.
In the United States, KPV has appeared in the administrative machinery around pharmacy compounding, where regulators maintain categories for bulk substances nominated for use by compounding pharmacies. KPV was placed in the category reserved for substances raising significant safety concerns in 2023, and its listing status changed again in 2026 in connection with withdrawn nominations rather than a new scientific conclusion. The key point for readers is that movement on or off such a list is not a safety verdict. It does not constitute approval, and removal from a cautionary list is not a finding that a substance is safe. Anyone relying on this for a decision should consult the agency's current published list directly, since it is revised periodically.
Elsewhere, KPV is typically supplied under a "research use only" label. That designation describes an intended use, laboratory research, and in practice signals the absence of pharmaceutical manufacturing requirements. It is not a quality grade and it is not a safety statement. Legal status for possession, import and sale varies substantially between jurisdictions, and a product that is lawfully sold in one country may be unlawful to import into another.
Readers wanting the broader framework for how to think about this class of products can consult our article on whether peptides are safe, which sets out the general distinction between approved medicines and research compounds.
How much of the risk comes from unregulated product quality?
A substantial part of it, and this is frequently the most underestimated element of the discussion. When no regulator oversees manufacturing, the contents of a vial are whatever the seller's supply chain produced, and published analytical work on this market is not reassuring.
In Talanta in 2018, Janvier and colleagues profiled the ten most frequently encountered falsified polypeptide drugs on the Belgian market, obtained from three suspected illegal internet pharmacies. They reported high variation in the amount of active substance per unit and low purity, ranging between 5 and 75 percent for the cysteine-containing peptides they examined. They also found elemental impurities: arsenic, present in its more toxic inorganic form, and lead, with multiple samples reaching concentrations up to ten times the ICH toxicity limit for parenteral medicines. The authors raised the prospect of sub-acute to chronic toxicity from long-term administration of such products.
Earlier, in Drug Testing and Analysis, Breindahl and colleagues analyzed melanotan II skin-tanning products sold illegally online. Vials labeled as containing 10 mg contained between 4.32 and 8.84 mg of the peptide, and vials from two of the shops contained unknown impurities at 4.1 to 5.9 percent. That example is instructive here precisely because melanotan II is also a melanocortin compound sold through the same informal channels.
Neither study examined KPV. The inference they support is about the distribution channel, not about the molecule: when peptides are bought outside regulated pharmaceutical supply, the label and the contents frequently diverge, and contaminants of toxicological significance have been documented. Applying that to KPV means accepting a specific consequence. If someone experiences a reaction after using an unregulated product, there is usually no way to determine whether the tripeptide, a synthesis byproduct, a heavy metal, a solvent residue or bacterial endotoxin was responsible.
Certificates of analysis do not resolve this. A certificate is supplied by, or commissioned by, the seller; it usually reports purity by a single chromatographic method on one batch; it commonly does not cover heavy metals, residual solvents, sterility or endotoxin; and the document cannot be independently linked to the specific vial in a buyer's hands. It is a commercial document, not a regulatory guarantee. Similar considerations apply to other compounds discussed for digestive conditions, as covered in our overview of peptides studied for gut health.
Who faces the most uncertainty, and what belongs in a conversation with a clinician?
Uncertainty is not distributed evenly. Several groups carry more of it, either because the underlying condition changes how a compound behaves or because the consequences of an unexpected effect are more serious.
- People with inflammatory bowel disease, who are the population most often targeted by KPV marketing. They frequently take immunomodulators or biologic agents, their intestinal transporter expression is altered by the disease itself, and substituting or adding an unstudied compound risks undertreating a condition that causes cumulative bowel damage when it is inadequately controlled.
- People with autoimmune conditions or known immunodeficiency, for whom any modulation of immune signaling has consequences that cannot be predicted from rodent colitis experiments.
- People who are pregnant, trying to conceive, or breastfeeding, where there is no reproductive or developmental toxicity data of any kind.
- People with active or past malignancy, given that immune surveillance is an inflammatory process and no relevant data exist.
- People taking multiple medicines, where an unstudied transporter interaction could alter the exposure of a drug that actually matters for their health.
If you are considering KPV, or already using it, the most useful thing you can do is tell your treating clinician, without editing the details. Bring the product, the label and any accompanying documentation, and state the route and how long you have used it. Clinicians cannot evaluate an exposure they do not know about, and concealment is a far larger risk than disclosure. If you are discussing it in advance, useful questions include how it might interact with your current prescriptions, what monitoring would make sense, which symptoms should prompt you to stop and seek care, and whether an evaluated option exists for your condition.
Because no characteristic adverse reaction pattern has been described for KPV, there is no specific warning sign list to offer. The general rule applied to any unapproved substance applies here: stop and seek medical attention for signs of a systemic reaction such as breathing difficulty, facial or throat swelling, widespread rash, fever, or rapidly worsening symptoms, and for signs of infection at an injection site. This advice is generic precisely because the specific information does not exist.
Finally, resist the framing that treats silence in the literature as a clean bill of health. A compound with no published human safety data is in an unknown position, and an unknown position can resolve in either direction once it is studied. The scientific interest in KPV is genuine and the preclinical findings in colitis models are legitimate research results. Neither of those facts tells you what KPV does to a human being over a year. For background on the molecule and its research history, see the complete KPV guide.
Medical disclaimer: this article is for educational purposes only, is not medical advice, and does not encourage the use of any substance. KPV is a research compound and is not approved for human use. Consult a qualified healthcare professional before making any health decision.
Frequently Asked Questions
Does KPV have documented side effects in humans?
Is KPV safe because it comes from a hormone the body already produces?
Can KPV cause skin darkening like other melanocortin compounds?
Does KPV taken by mouth cause digestive upset?
Have allergic reactions to KPV been reported?
Could KPV interfere with prescription medicines?
Is KPV approved by the FDA or the EMA?
Does a certificate of analysis mean a KPV product is safe?
Recommended products
Research peptides selected for quality and purity:
KPV
Anti-Inflammatory Peptide
KPV Oral
Oral Gut Peptide
BPC-157
Healing Peptide
TB-500
Recovery Peptide
Test your knowledge
Quick quiz · 6 questions
Scientific Sources
- Dalmasso G, Charrier-Hisamuddin L, Nguyen HT, Yan Y, Sitaraman S, Merlin D (2008). PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation. Gastroenterology. (PubMed)
- Kannengiesser K, Maaser C, Heidemann J, et al. (2008). Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of inflammatory bowel disease. Inflammatory Bowel Diseases, 14(3):324-331. (academic.oup.com)
- Brzoska T, Luger TA, Maaser C, Abels C, Böhm M (2008). Alpha-melanocyte-stimulating hormone and related tripeptides: biochemistry, antiinflammatory and protective effects in vitro and in vivo, and future perspectives for the treatment of immune-mediated inflammatory diseases. Endocrine Reviews, 29(5):581-602. (PubMed)
- Gravina AG, et al. (2023). The Melanocortin System in Inflammatory Bowel Diseases: Insights into Its Mechanisms and Therapeutic Potentials. Cells, 12(14):1889. (PMC)
- Luger TA, Brzoska T (2007). Alpha-MSH related peptides: a new class of anti-inflammatory and immunomodulating drugs. Annals of the Rheumatic Diseases, 66(Suppl 3):iii52-iii55. (ard.bmj.com)
- Laroui H, Dalmasso G, Nguyen HTT, Yan Y, Sitaraman SV, Merlin D (2010). Drug-loaded nanoparticles targeted to the colon with polysaccharide hydrogel reduce colitis in a mouse model. Gastroenterology, 138(3):843-853.
- Janvier S, et al. (2018). Impurity profiling of the most frequently encountered falsified polypeptide drugs on the Belgian market. Talanta.
- Breindahl T, et al. (2015). Identification and characterization by LC-UV-MS/MS of melanotan II skin-tanning products sold illegally on the Internet. Drug Testing and Analysis, 7(2):164-172.
- Cutuli M, Cristiani S, Lipton JM, Catania A (2000). Antimicrobial effects of alpha-MSH peptides. Journal of Leukocyte Biology, 67(2):233-239.